STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRNA
  4. [Form 4] Moderna, Inc. Insider Trading Activity

Director at Moderna (NASDAQ: MRNA) granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Moderna, Inc. director Nader Francois reported equity compensation awards. He received 4,185 restricted stock units and a stock option for 6,454 shares of common stock, both granted at no cost on May 6, 2026. The option has a $48.79 exercise price and expires on May 6, 2036.

Both the stock option and the RSUs vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service. Following these grants, his reported derivative holdings from these awards match the granted amounts.

Positive

  • None.

Negative

  • None.
Insider Nader Francois
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 6,454 $0.00 --
Grant/Award Restricted Stock Units 4,185 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 6,454 shares (Direct, null); Restricted Stock Units — 4,185 shares (Direct, null)
Footnotes (1)
  1. This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Restricted stock units convert into common stock on a one-for-one basis. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
RSU grant size 4,185 units Restricted stock units granted May 6, 2026
Stock option grant size 6,454 options Options on common stock granted May 6, 2026
Option exercise price $48.79 per share Stock Option (Right to Buy) exercise price
Option expiration May 6, 2036 Expiration date of stock option grant
Vesting date Earlier of May 6, 2027 or next annual meeting Vesting condition for RSUs and options, subject to service
Post-grant RSU holdings 4,185 units Total RSUs following transaction for this award
Post-grant option holdings 6,454 options Total options following transaction for this grant
Restricted Stock Units financial
"The shares subject to this restricted stock unit award will vest in full"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 48.7900"
vested and exercisable financial
"This option will become fully vested and exercisable on the earlier of May 6, 2027"
Annual Meeting of Shareholders financial
"on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
one-for-one basis financial
"Restricted stock units convert into common stock on a one-for-one basis"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nader Francois
(Last)(First)(Middle)
C/O MODERNA, INC.
325 BINNEY STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02142
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$48.7905/06/2026A6,454 (1)05/06/2036Common Stock6,454$06,454D
Restricted Stock Units(2)05/06/2026A4,185 (3) (3)Common Stock4,185$04,185D
Explanation of Responses:
1. This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
2. Restricted stock units convert into common stock on a one-for-one basis.
3. The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
/s/ James Dillon, as Attorny-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Moderna (MRNA) director Nader Francois report on this Form 4?

Director Nader Francois reported equity compensation awards from Moderna. He received 4,185 restricted stock units and a stock option for 6,454 shares, both granted on May 6, 2026, as part of his board compensation, rather than open-market share purchases or sales.

How many Moderna (MRNA) restricted stock units did Nader Francois receive?

Nader Francois received 4,185 restricted stock units from Moderna. These RSUs convert into common stock on a one-for-one basis and are scheduled to vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to his continued service.

What are the terms of Nader Francois’s new Moderna (MRNA) stock options?

He was granted stock options for 6,454 shares of Moderna common stock. The options have a $48.79 exercise price, were granted on May 6, 2026, and will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting, subject to continued service.

Are these Moderna (MRNA) Form 4 transactions open-market buys or compensation grants?

These transactions are compensation-related grants, not open-market trades. The Form 4 shows awards of restricted stock units and stock options coded as acquisitions under transaction code “A,” reflecting grants or awards provided to director Nader Francois for his service on Moderna’s board.

When will Nader Francois’s Moderna (MRNA) RSUs and options vest?

Both the RSUs and stock options vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders. Vesting is conditioned on Nader Francois’s continued service, meaning he must remain in his director role through the applicable vesting date.

What does the one-for-one RSU conversion mean for Moderna (MRNA) shares?

The one-for-one conversion means each restricted stock unit becomes one share of Moderna common stock when it vests. For Nader Francois’s 4,185 RSUs, a full vesting would result in 4,185 common shares being issued to him, assuming all vesting conditions are satisfied.